Tau is reduced in AD plasma and validation of employed ELISA methods

American Journal of Neurodegenerative Diseases

Volumn 1, Issue 1, 2012, Pages 99-106

  Larry Sparks, D ^a   Kryscio, Richard J ^b   Sabbagh, Marwan N ^a   Ziolkowski, Chuck ^a   Lin, Yushun ^b   Sparks, Lisa M ^a   Liebsack, Carolyn ^a   Johnson Traver, Sherry ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Circulating tau levels; Mild cognitive impairment

Indexed keywords

TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; COGNITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; SERUM; VALIDATION PROCESS; VERY ELDERLY; WESTERN BLOTTING;

EID: 84980054122     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Strozyk D, Launer LJ, Adlard PA, Cherny RA, Tsatsanis A, Volitakis I, Blennow K, Petrovitch H, White LR and Bush AI. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Nerobiol Aging 2009; 7: 1069-1077.
2. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, Bouwman FH, Schonknecht P, Schoonenboom NS, Andreasen N, Wallin AK, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K and Hampel H. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007; 69: 2205-2212.
3. Olsson A, Vanderstichele H, Andreasen N and al e. Simultaneous measurement of beta-amyloid (1-42), total tau and phosphorylated tau (Thr81) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-345.
4. Vanderstichele H, De Meyer G, Shapiro F, Engelborghs S, De Deyn PP, Shaw LM and Trojanowski JQ. Alzheimer's Disease Biomarkers: From concept to clinical utility. In: Galimberti D, Scarpini E, editors. Biomarkers for Early Diagnosis of Alzheimer's Disease. Nova Science Publishers; 2008. p. 81-122.
5. de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski RP, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J and Rusinek H. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 2007; 1097: 114-145.
6. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L and Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geratr Cogn Disord 2007; 23: 316-320.
7. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
8. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Alsen PS, Peterson RC, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ and Initiative AsDN. Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects. 2009; 1-12.
9. Shaw LM, Korecka M, Clark CM, Lee VM and Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Reviews Drug Discovery 2007; March 9: 2176.
10. Ringman J, Younkin S, Pratico D, Seltzr W, Cole G, Geschwind D, Rodriquez-Aqudelo Y and al e. Biochemical markrs in persons with preclinical familial Alzheimer disease. Neurology 2008; Jul 8;: 85-92.
11. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark C, Aisen P, Petersen R, Biennow K, Soares H, Simon AJ, Lewczuk P, Dean R, Siemers E, Potter W, Weiner M and al e. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's Dement 2010; May 230-238.
12. Blennow K, Hamm K, Weiner MW and Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 2010: 6(3).
13. Scheurich A, Urban P, Koch-Khoury N and Fellgiebel A. CSF phospho-tau is independent of age, cognitive status and gender of neurological patients. J Neurol Nerosurge Psychiatry 2010; Apr: 609-614.
14. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L and Trojanowski JQ. Diagnosisindependent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neorol 2010; 67(8): 949-956.
15. Rosenmann H, Meiner Z, Geylis V, Abramsky O and Steinitz M. Detection of circulating antibod ies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006; Dec 20: 90-93.
16. Hampel H, Blennow K, Shaw L, Hoessler Y, Zetterberg H and Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010; Jan: 30-40.
17. Ingelsson M, Blomberg M, Benedikz E, Wahlund LO, Karlsson E, Vanmachelen E and Lannfelt L. Tau Immunoreactivity detected in Human Plasma, But no Obvious Increase in Dementia. Dementia and Geriatric Cognitive Disorders 1999; 10:: 442-445.
18. Mortberg, Zetterberg H, Nordmark J, Blennow K, Catry C, Daecraemer H, Vanmechelen E and Rbertsson S. Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia. Acta Anaesthesiol Scand 2011; 55: 1132-1138.
19. Noguchi-Shinohara M, Hamaguchi T, Nozaki I, Sakai K and Yamada M. Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. J Neurol 2011; 258: 1464-1468.
20. Bartosik-Psujek H, Psujek M, Jaworski J and Stelmasiak Z. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand 2011; 123: 252-256.
21. Wunderlich M, Lins H, Skalej M, Wallesch C and Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term otcome in acute ischemic stroke. Clinical Neuology & Neurosurgery 2006; 108: 558-563.
22. Bielewicz J, Kurzepa J, Czekajska-chehab E, Stelmasiak Z and Bartosik-Psujek H. Does Serum Tau Protein Predict the Outcome of Patients with Ischemic Stroke? J Mol Neurosci 2011; 43: 241-245.
23. Liliang P-C, Liang C-L, Weng H-C, Lu K, Wang KW, Chen H-J and Chuang J-H. tau Proteins in Serum Predict Outcome After Severe Traumatic Brain Injury. Journal of Surgical Research 2010; 160: 302-307.
24. Guzel A, Karasalihoglu S, Aylanc H, Temizoz O and Hicdonmez T. Validity of serum tau protein levels in pediatric patients with minor head trauma. American Journal of Emergency Medicine 2010; 28: 399-403.
25. Liliang P-C, Liang C-L, Lu K, Wang K-W, Weng HC, Hsieh C-H, Tsai Y-D and Chen H-J. Relationship between injury severity and serum tau protein levels in traumatic brain injured rats. Resuscitation 2010; 10: 1205-1208.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM. Clinical diagnosis of Alzheimer's diseae. Neurology 1984; 34: 939-944.
27. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000; 15: 93-101.
28. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194.
29. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L and Winblad B. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
30. Folstein MF, Folstein SE and McHugh PR. "Mini-Mental State:" A practical method for grading the mental state of patients for the clinician. J Psychiatric Res 1975; 12: 189-198.
31. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France, 1964.
32. Taylor EM. Psychological appraisal of children with cerebral deficits. Cambridge, MA: Harvard University Press, 1959.
33. Borod JC, Goodglass H and Kaplan E. Normative data on the Boston Diagnostic Aphasia Examination, Parietal Lobe battery and the Boston Naminig Test. Journal of Clinical Neuropsychology 1980; 2: 209-216.
34. Sparks DL, Ziolkowski C, Lawmaster T and Martin T. Influence of water quality on cholesterolinduced tau pathology: Preliminary data. IJAD 2011; 2011: ID #987023.
35. Straten G, Eschweiler GW, Maetzler W, Laske C and Leyhe T. Glial Cell-Line Derived Neurotrophic Factor (GDNF) Concentrations in Cerebrospinal Fluid and Serum of Patients with Early Alzheimer's Disease and Normal Controls. Journal of Alzheimer's Disease 2009; 18: 331-337.